Giles Whalen to Antineoplastic Agents
This is a "connection" page, showing publications Giles Whalen has written about Antineoplastic Agents.
Connection Strength
0.609
-
Rajeshkumar BR, Paliwal S, Lambert L, Grossman SR, Whalen GF. Treatment of peritoneal carcinomatosis with intraperitoneal administration of Ad-hARF. J Surg Res. 2015 Jul; 197(1):85-90.
Score: 0.306
-
Thomas JS, Siu LL, Ingham M, Azad NS, Meyer CF, Olszanski AJ, Whalen GF, Camacho LH, Hu JS, Hanna DL, Cheng PM, Abdul Razak AR, Abbate F, Mahmood S, Walters IB, Bender LH, El-Khoueiry AB. Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study. EBioMedicine. 2025 Nov; 121:105980.
Score: 0.160
-
Furman MJ, Picotte RJ, Wante MJ, Rajeshkumar BR, Whalen GF, Lambert LA. Higher flow rates improve heating during hyperthermic intraperitoneal chemoperfusion. J Surg Oncol. 2014 Dec; 110(8):970-5.
Score: 0.074
-
Straza MW, Paliwal S, Kovi RC, Rajeshkumar B, Trenh P, Parker D, Whalen GF, Lyle S, Schiffer CA, Grossman SR. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle. 2010 Sep 15; 9(18):3740-50.
Score: 0.056
-
Piperdi M, McDade TP, Shim JK, Piperdi B, Kadish SP, Sullivan ME, Whalen GF, Tseng JF. A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database. HPB (Oxford). 2010 Apr; 12(3):204-10.
Score: 0.014